Diferencia entre revisiones de «Valganciclovir»
(Created page with "==Administration== *Type: Antiviral *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: ==Adult Dosing== *CMV infection: 900 mg PO BID *CMV prophylaxis:...") |
(Restore original dosing content alongside dynamic SMW tables) |
||
| (No se muestran 2 ediciones intermedias de 2 usuarios) | |||
| Línea 8: | Línea 8: | ||
*CMV infection: 900 mg PO BID | *CMV infection: 900 mg PO BID | ||
*CMV prophylaxis: 900 mg PO daily | *CMV prophylaxis: 900 mg PO daily | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Valganciclovir]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Neonatal CMV infection: 17 mg/kg PO daily BID x 12 weeks, then 17 mg/kg daily until 1 year of age | *Neonatal CMV infection: 17 mg/kg PO daily BID x 12 weeks, then 17 mg/kg daily until 1 year of age | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Valganciclovir]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug pregnancy categories|Pregnancy Rating]]: | *[[Drug pregnancy categories|Pregnancy Rating]]: Category C, fetal risk cannot be ruled out | ||
*Lactation risk: infant risk cannot be ruled out | *Lactation risk: infant risk cannot be ruled out | ||
*Renal dosing | *Renal dosing | ||
| Línea 55: | Línea 81: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Revisión actual - 02:38 20 mar 2026
Administration
- Type: Antiviral
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names:
Adult Dosing
- CMV infection: 900 mg PO BID
- CMV prophylaxis: 900 mg PO daily
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| CMV retinitis | 900mg PO q12hrs x 14 days then 900mg PO q24hrs x 7 days | Severe vision threatening with intraocular implant |
| CMV retinitis | 900mg PO q12hrs x 21 days then 900mg PO q24hrs x 7 days | Peripheral lesions |
Pediatric Dosing
- Neonatal CMV infection: 17 mg/kg PO daily BID x 12 weeks, then 17 mg/kg daily until 1 year of age
Indications by Disease
Special Populations
- Pregnancy Rating: Category C, fetal risk cannot be ruled out
- Lactation risk: infant risk cannot be ruled out
- Renal dosing
- CrCl 40-59 mL/min: 450 mg BID
- CrCl 25-39 mL/min: 450 mg once daily
- CrCl 10-24 mL/min: 450 mg every 2 days
- CrCl < 10 mL/min or on HD: not recommended
- Hepatic dosing:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anemia/aplastic anemia, leukopenia, thrombocytopenia, pancytopenia
Common
- Nausea/vomiting, diarrhea
- Graft rejection
- Headache
- URI
- UTI
- Fever
- Tremor
Pharmacology
- Half-life: 4-10h
- Metabolism: Hepatic
- Excretion: Renal
Mechanism of Action
- Inhibits viral DNA synthesis